Home / Daily Healthy Tips / Deep Lens Raises $14 million to Improve AI-driven Pathology (Interview)

Deep Lens Raises $14 million to Improve AI-driven Pathology (Interview)

Deep Lens Raises $14 million to Improve AI-driven Pathology (Interview)

Deep Lens is an AI-driven virtual pathology corporate primarily based in Ohio. They’re these days operating with Worldwide Clinical Trials to fast-track affected person enrollment into scientific trials. This week, they introduced a a hit Series A financing spherical of $14 million.

“Since our inception, we’ve benefited from a tremendous group of investors, which now includes the world class team at Northpond Ventures,” mentioned Deep Lens co-founder and CEO Dave Billiter in a press liberate observation. “This Series A financing is further validation of the value of our industry-changing approach to digital pathology in delivering the right cancer diagnoses faster and accelerating oncology trial recruitment and timelines.”

We wrote about Deep Lens closing October once they exited stealth mode and got seed fairness investment. We stuck up once more with Dave Billiter and Simon Arkell, co-founder and President, respectively, to achieve perception into their investment and long run objectives in opposition to a greater virtual pathology carrier.


Ben Ouyang, Medgadget: How did you in finding the buyers for the Series A financing?

Deep Lens: The international oncology trials marketplace is drawing near $65 billion and Northpond Ventures have been having a look on the marketplace. Their analysts finished their overview of the marketplace and reached out to us. They discovered we have been the most productive supplier within the area as a result of we now have a industry style that may give us essential mass with pathologists. We can leverage that footprint for its knowledge and feature get entry to to sufferers that may be known for scientific trials.


Medgadget: What will the cash assist you to do?

Deep Lens: The financing will support in us increasing our tool construction and knowledge science groups, in addition to enlarge advertising and gross sales headcount. We will likely be creating extra fashions and techniques primarily based upon tumor sorts and other remedies. We will proceed to upload extra options to the platform to reinforce the workflow of pathologists, scientific analysis coordinators, important investigators, and biopharma.

The AI strategies we now have already created have confirmed to surpass all printed literature in the case of accuracy. We will broaden extra of the ones and embed them in VIPER in order that they may be able to be used to strengthen pathology uptake and force additional adoption of virtual pathology. Without going into our proprietary strategies in an excessive amount of element, what we will be able to say is that VIPER will likely be used to establish and fit sufferers to suitable scientific trials a lot quicker than any present strategies, thereby serving to trial sponsors establish extra sufferers and strengthen recruitment charges, and compress timelines for scientific trials.


Medgadget: Have there been any traits within the tech since we spoke closing 12 months?

Deep Lens: Absolutely. We have added extra good judgment according to a tumor sort and AI strategies into the workflow of VIPER. We have evolved AI that has confirmed to actually exceed any printed literature for tumor id fashions in breast most cancers and lymphoma. We have additionally finished improvements to the picture viewer inside VIPER.

Billiter: The screenshot is of the VIPER three.zero model, which displays us embedding AI strategies within the workflow of case evaluations. The AI approach known on this symbol is of our Cell Counting set of rules the place the annotations point out the mobile nuclei. The darker circles of what we now have known in our AI is the true mobile nuclei, and the sunshine pink is the cytoplasm of the mobile contained inside the mobile membrane. This is certainly one of a number of strategies that we’re offering to pathologists of their person account of VIPER. The algorithms that we’re integrating into the workflow of VIPER will likely be applied for each forged and liquid tumors. The VIPER platform is a multi-purpose resolution and is used by pathologists for organising flooring reality after which allows AI fashions and techniques to be evolved in an iterative type. All of this knowledge is tracked within the VIPER database which allows a deeper figuring out to produce our AI.

Medgadget: What recommendation do you’ve for our readers in getting a era going?

Deep Lens: I’d suggest organising a continual comments loop from the end-users and to be extraordinarily centered at the product marketplace are compatible. We perceive this procedure as a result of VIPER used to be evolved over a duration of 10 years and used to be utilized by taking part pathologists on dozens of worldwide research. We iterated on their comments and supplied a product that discovered product marketplace are compatible.


Medgadget: What’s the largest hurdle you’re dealing with at this time?

Deep Lens: Hiring. We are swiftly increasing our group and discovering the correct people as quick as conceivable to reinforce scaling our operation. We are having a look throughout a lot of industries for tool builders, AI knowledge scientists, AI builders, gross sales, advertising and industry construction team of workers.

Related announcement: Deep Lens Closes $14 Million Series A Financing to Further Advance Digital AI Pathology Platform for Clinical Trial Recruitment

Link: Deep Lens…

(serve as(d, s, identification) (file, ‘script’, ‘facebook-jssdk’));

Check Also

Lower Body Workout

Lower Body Workout Trainer Sydney Torabi takes you thru an entire decrease frame exercise to …

Leave a Reply

Your email address will not be published. Required fields are marked *